IMC-F106C in Advanced Cancers

What is the Purpose of this Study?

The purpose of this study is to determine the safety and effectiveness of an investigational immunotherapeutic drug called IMC-F106C in multiple cancers (endometrial, ovarian, melanoma, ocular melanoma, triple-negative breast, lung, and bladder cancer) expressing a specific protein. IMC-F106C has been developed to activate the body’s own immune system to fight tumors overexpressing a specific protein. Patients will be eligible for the study if they express this protein.

The study will be divided into several parts: a phase I monotherapy group looking for the appropriate dose, phase I combination therapy groups with other immunotherapies, and an expanded phase II group, once the appropriate dose is established. The dose of IMC-F106C participants receive will depend on when they join the study. The first group of patients will receive a dose of the drug, with each new group receiving a higher dose. 


Eligibility

  • ECOG PS 0 or 1
  • HLA-A*02:01 positive
  • PRAME positive tumor
  • Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies
Show more

Where can I participate?

Cedars-Sinai Cancer at The Angeles Clinic and Research Institute : Saba Mukarram

More about this Clinical Trial

What is the full name of this clinical trial?

IMC-F106C-101: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A 02:01-Positive Participants with Advanced PRAME-Positive Cancers

Study Details
Disease Type/Condition

Melanoma, Other Skin, Other Urinary, Ovary, Unknown Sites

Principal Investigator

Hamid, Omid

Co-Investigators

Ani Balmanoukian, Cathie T Chung, Iryna Singh, Justin Moyers, Kristopher Wentzel, Mark Faries, Michelle Offner, Navid Hafez

Age Group

Adult

Phase

I/II

IRB Number

STUDY00000513

ClinicalTrials.gov ID

NCT04262466

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Saba Mukarram

Phone
+1 310-231-2181
Email
MukarramS@cshs.org
Study Detail
Disease Type/Condition

Melanoma, Other Skin, Other Urinary, Ovary, Unknown Sites

Principal Investigator

Hamid, Omid

Age Group

Adult

Phase

I/II

IRB Number

IMC-F106C-101

ClinicalTrials.gov ID

NCT04262466

Key Eligibility
ClinicalTrials.gov

Contact
Name

Saba Mukarram

Phone
+1 310-231-2181
Email
MukarramS@cshs.org